Horizons 2010, Clare S. Wilkins:
Since 2006, we have administered over 400 Ibogaine treatments for patients representing a cross section of chemical dependencies. We will be presenting on data culled over a four-year period. Outcomes will be measured in terms of detoxification, recidivism, and in some patients, Quality of Life surveys. Preliminary findings demonstrate Ibogaine to be a significant tool in the recovery process, and call for more intensive aftercare, integration & follow up therapies.
Clare S. Wilkins is Director of Pangea Biomedics, Tijuana, Mexico. She is a former IV heroin user and methadone patient who, in 2005, shed her chemical dependencies with Ibogaine, a natural extract of the African root Tabernanthe Iboga. Ibogaine is classified in the USA as a Schedule 1 drug with “no currently accepted medical use,” even though numerous clinical and preclinical studies have shown that Ibogaine reduces rates of self administration of opiates, cocaine, amphetamines, alcohol & nicotine, significantly attenuates opiod withdrawal symptoms, improves depression scores, and greatly reduces craving subsequent to detoxification.
In 2006, Miss Wilkins created Pangea Biomecics in Tijuana, Mexico where she has facilitated over 400 Ibogaine treatments, and is working with the Multidisciplinary Association for Psychedelic Studies to study the long-term effects of Ibogaine. As a member of INPUD and INWUD international drug user rights organizations, she is devoted to reducing stigma, promoting the health and defending the rights of people who use drugs. She passionately believes in every human’s basic right to medicine.